|
|
||||||||
-Peptide in Microglia Is Differentially Modulated by C1q1

*
Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697; and
Center for Pharmaceutical Biotechnology, University of Colorado Health Sciences Center, University of Colorado, Denver, CO 80262
Microglial ingestion of the amyloid
-peptide (A
) has been
viewed as a therapeutic target in Alzheimers disease, in that
approaches that enhance clearance of A
relative to its production
are predicted to result in decreased senile plaque formation, a
proposed contributor to neuropathology. In vitro, scavenger receptors
mediate ingestion of fibrillar A
(fA
) by microglia. However, the
finding that cerebral amyloid deposition in a transgenic mouse model of
Alzheimers disease was diminished by inoculation with synthetic A
has suggested a possible therapeutic role for anti-A
Ab-mediated
phagocytosis. Microglia also express C1qRP, a receptor for
complement protein C1q, ligation of which in vitro enhances
phagocytosis of immune complexes formed with IgG levels below that
required for optimal FcR-mediated phagocytosis. The data presented here
demonstrate FcR-dependent ingestion of A
-anti-A
complexes
(IgG-fA
) by microglia that is a function of the amount of Ab used to
form immune complexes. In addition, C1q incorporated into IgG-fA
enhanced microglial uptake of these complexes when they contained
suboptimal levels of anti-A
Ab. Mannose binding lectin and lung
surfactant protein A, other ligands of C1qRP, also enhanced
ingestion of suboptimally opsonized IgG-fA
, whereas control proteins
did not. Our data suggest that C1qRP-mediated events may
promote efficient ingestion of A
at low Ab titers, and this may be
beneficial in paradigms that seek to clear amyloid via FcR-mediated
mechanisms by minimizing the potential for destructive Ab-induced
complement-mediated processes.
This article has been cited by other articles:
![]() |
K. N. Green, L. M. Billings, B. Roozendaal, J. L. McGaugh, and F. M. LaFerla Glucocorticoids Increase Amyloid-beta and Tau Pathology in a Mouse Model of Alzheimer's Disease. J. Neurosci., August 30, 2006; 26(35): 9047 - 9056. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Fraser, S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford, and A. J. Tenner C1q and MBL, components of the innate immune system, influence monocyte cytokine expression J. Leukoc. Biol., July 1, 2006; 80(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Koenigsknecht and G. Landreth Microglial Phagocytosis of Fibrillar {beta}-Amyloid through a {beta}1 Integrin-Dependent Mechanism J. Neurosci., November 3, 2004; 24(44): 9838 - 9846. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Das, V. Howard, N. Loosbrock, D. Dickson, M. P. Murphy, and T. E. Golde Amyloid-{beta} Immunization Effectively Reduces Amyloid Deposition in FcR{gamma}-/- Knock-Out Mice J. Neurosci., September 17, 2003; 23(24): 8532 - 8538. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Wilcock, G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K. E. Ugen, M. N. Gordon, and D. Morgan Intracranially Administered Anti-Abeta Antibodies Reduce beta -Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation J. Neurosci., May 1, 2003; 23(9): 3745 - 3751. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Furlan, E. Brambilla, F. Sanvito, L. Roccatagliata, S. Olivieri, A. Bergami, S. Pluchino, A. Uccelli, G. Comi, and G. Martino Vaccination with amyloid-{beta} peptide induces autoimmune encephalomyelitis in C57/BL6 mice Brain, February 1, 2003; 126(2): 285 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Mitrasinovic and G. M. Murphy Jr. Accelerated Phagocytosis of Amyloid-beta by Mouse and Human Microglia Overexpressing the Macrophage Colony-stimulating Factor Receptor J. Biol. Chem., August 9, 2002; 277(33): 29889 - 29896. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Jantzen, K. E. Connor, G. DiCarlo, G. L. Wenk, J. L. Wallace, A. M. Rojiani, D. Coppola, D. Morgan, and M. N. Gordon Microglial Activation and beta -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice J. Neurosci., March 15, 2002; 22(6): 2246 - 2254. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |